Utrecht Stroke Center, Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands.
Lancet Neurol. 2011 Apr;10(4):349-56. doi: 10.1016/S1474-4422(11)70017-5.
More and more patients survive aneurysmal subarachnoid haemorrhage (aSAH), with case fatality decreasing by 17% in absolute terms over the past three decades and incidence remaining relatively stable at nine per 100,000 patient-years. The mean age at which aSAH occurs is reasonably young at 55 years, and people of this age in the general population have a good life expectancy. However, there are few data for life expectancy after aSAH, and the risks of late recurrent aSAH and other vascular diseases are unclear. The course of associated long-term physical and cognitive deficits after aSAH is not well established, leading to questions about potential outcomes to quality of life and working capacity, as well as best clinical practices.
越来越多的动脉瘤性蛛网膜下腔出血(aSAH)患者幸存下来,在过去三十年中,绝对病死率下降了 17%,而发病率在每 10 万人年中相对稳定在 9 例。aSAH 发生的平均年龄相当年轻,为 55 岁,而一般人群中这个年龄段的人预期寿命较长。然而,关于 aSAH 后的预期寿命数据很少,晚期复发性 aSAH 和其他血管疾病的风险尚不清楚。aSAH 后相关长期身体和认知缺陷的病程尚不清楚,导致对潜在的生活质量和工作能力以及最佳临床实践的结果产生疑问。